OncoSec Appoints Sara M. Bonstein as Chief Financial Officer and Chief Operating Officer Jul 16, 2018
OncoSec Presents Update on PISCES/KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial in Combination with Merck's KEYTRUDA® for Metastatic Melanoma at the ASCO 2018 Annual Meeting Jun 4, 2018
OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer May 8, 2018
OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting Apr 26, 2018
OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting Apr 3, 2018
